LIVE

REGN

Regeneron Pharmaceuticals, Inc.

REGN

NASDAQ·Healthcare·Biotechnology·Mkt cap $64.4B

$654.27

▲ +4.73%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$532.60 - $821.11

P/E

15.94

Fwd P/E

14.45

Beta

0.24

Div Yield

0.58%

Avg Vol

978.5K

Shares Out

103.0M

Mkt Cap

$64.4B

Price action

Price chart

Up 14.1% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Advanced proprietary antibody technologies
  • Extensive research and development capabilities
  • Strategic pharmaceutical partnerships
  • Diversified therapeutic portfolio
▼

Bear Case

1 risk

  • Low volatility (beta 0.2).

Growth

Stable outlook

Continued innovation in biologics

Value

Undervalued - trading well below Biotech & Therapeutics peers

Momentum

Weak

-18.0% over 3m

Quality

Excellent

Excellent business quality

Dividend

Modest

0.58% yield

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 27, 2026

“
Q2 26 RECAP

APR 29, 2026

Reported EPS of $9.47 vs $8.91 consensus (+6.3% surprise). Revenue of $3.6B vs $3.5B expected (+3.6%). Beat on both top and bottom lines.

EPS beat +6.3%
Rev beat +3.6%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+6.3%

Next: Apr 27, 2026

Revenue trend · last 8Q

—

—

+10%

-4%

+4%

+1%

+3%

+19%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$3.5B

$3.7B

$3.8B

$3.0B

$3.7B

$3.8B

$3.9B

$3.6B

Margins · last 8Q

Gross

81.4%

Operating

17.8%

Profit

20.2%

View full earnings history →

Wall Street consensus

18 analysts · 72% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

13

72%

Hold

5

28%

Sell

0%

Median Price Target

$825.00

▲ +26.1% vs $654.27

Low $641.00
Median $825.00
High $995.00

Latest: RBC Capital · Jun 22, 2026

13 analysts covering

View full analyst page →

vs Industry

How REGN stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.